Target Information
| Target General Information | Top | |||||
|---|---|---|---|---|---|---|
| Target ID |
T25537
(Former ID: TTDI01585)
|
|||||
| Target Name |
Mitogen-activated protein kinase (MAPK)
|
|||||
| Synonyms |
MAPK; Extracellular signal-regulated kinase; ERK
Click to Show/Hide
|
|||||
| Gene Name |
NO-GeName
|
|||||
| Target Type |
Clinical trial target
|
[1] | ||||
| Disease | [+] 2 Target-related Diseases | + | ||||
| 1 | Keratosis pilaris [ICD-11: ED56] | |||||
| 2 | Solid tumour/cancer [ICD-11: 2A00-2F9Z] | |||||
| BioChemical Class |
Kinase
|
|||||
| UniProt ID | ||||||
| Drugs and Modes of Action | Top | |||||
|---|---|---|---|---|---|---|
| Clinical Trial Drug(s) | [+] 2 Clinical Trial Drugs | + | ||||
| 1 | GBL-310 | Drug Info | Phase 2 | Keratosis | [2] | |
| 2 | LTT462 | Drug Info | Phase 1 | Solid tumour/cancer | [4] | |
| Mode of Action | [+] 1 Modes of Action | + | ||||
| Inhibitor | [+] 16 Inhibitor drugs | + | ||||
| 1 | GBL-310 | Drug Info | [1] | |||
| 2 | LTT462 | Drug Info | [4] | |||
| 3 | Bidentate ligands of Markush derivative 1 | Drug Info | [5] | |||
| 4 | Bidentate ligands of Markush derivative 2 | Drug Info | [5] | |||
| 5 | PMID25991433-Compound-B1 | Drug Info | [6] | |||
| 6 | PMID25991433-Compound-B3 | Drug Info | [6] | |||
| 7 | PMID25991433-Compound-C2 | Drug Info | [6] | |||
| 8 | PMID25991433-Compound-C3 | Drug Info | [6] | |||
| 9 | PMID25991433-Compound-J1 | Drug Info | [6] | |||
| 10 | PMID25991433-Compound-J6 | Drug Info | [6] | |||
| 11 | PMID25991433-Compound-L | Drug Info | [6] | |||
| 12 | PMID25991433-Compound-L2 | Drug Info | [6] | |||
| 13 | PMID25991433-Compound-L3 | Drug Info | [6] | |||
| 14 | PMID25991433-Compound-P3 | Drug Info | [6] | |||
| 15 | PMID25991433-Compound-Q2 | Drug Info | [6] | |||
| 16 | U0126 | Drug Info | [7] | |||
| Drug Property Profile of Target | Top | |
|---|---|---|
| (1) Molecular Weight (mw) based Drug Clustering | (2) Octanol/Water Partition Coefficient (xlogp) based Drug Clustering | |
|
|
||
| (3) Hydrogen Bond Donor Count (hbonddonor) based Drug Clustering | (4) Hydrogen Bond Acceptor Count (hbondacc) based Drug Clustering | |
|
|
||
| (5) Rotatable Bond Count (rotbonds) based Drug Clustering | (6) Topological Polar Surface Area (polararea) based Drug Clustering | |
|
|
||
| "RO5" indicates the cutoff set by lipinski's rule of five; "D123AB" colored in GREEN denotes the no violation of any cutoff in lipinski's rule of five; "D123AB" colored in PURPLE refers to the violation of only one cutoff in lipinski's rule of five; "D123AB" colored in BLACK represents the violation of more than one cutoffs in lipinski's rule of five | ||
| References | Top | |||||
|---|---|---|---|---|---|---|
| REF 1 | WO patent application no. 2010,0456,51, Methods for analyzing drug response. | |||||
| REF 2 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800025788) | |||||
| REF 3 | ClinicalTrials.gov (NCT05538130) A PHASE 1A/B OPEN-LABEL MASTER STUDY OF PF-07799544 AS A SINGLE-AGENT AND IN COMBINATION WITH OTHER TARGETED AGENTS IN PARTICIPANTS WITH ADVANCED SOLID TUMORS. U.S.National Institutes of Health. | |||||
| REF 4 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||||
| REF 5 | Leucine-rich repeat kinase 2 inhibitors: a patent review (2014-2016).Expert Opin Ther Pat. 2017 Jun;27(6):667-676. | |||||
| REF 6 | c-Jun N-terminal kinase inhibitors: a patent review (2010 - 2014).Expert Opin Ther Pat. 2015;25(8):849-72. | |||||
| REF 7 | Intravenous administration of MEK inhibitor U0126 affords brain protection against forebrain ischemia and focal cerebral ischemia. Proc Natl Acad Sci U S A. 2001 Sep 25;98(20):11569-74. | |||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.